Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome p450 systems

Molecular Pharmacology

Volumn 83, Issue 6, 2013, Pages 1209-1217

  Henderson, Colin J ^a   McLaughlin, Lesley A ^a   Wolf, C Roland ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME B5; CYTOCHROME B5 REDUCTASE; CYTOCHROME P450; MIDAZOLAM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME ACTIVITY; FATTY LIVER; GENETIC MODEL; HEPATOMEGALY; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TURNOVER TIME; ANIMAL; C57BL MOUSE; ELECTRON; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; MOUSE MUTANT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROME-B(5) REDUCTASE; CYTOCHROMES B5; ELECTRONS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSOMES, LIVER; MIDAZOLAM;

MLCS; MLOWN;

EID: 84877805503     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.084616     Document Type: Article

References (40)

1. Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, and Stiborova M (2006) Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: Evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett 234: 220-231.
2. Arlt VM, Singh R, Stiborová M, Gamboa da Costa G, Frei E, Evans JD, Farmer PB, Wolf CR, Henderson CJ, and Phillips DH (2011) Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-amino-1-methyl-6- phenylimidazo[4,5-b] pyridine-DNA adduct formation in P450 reductase conditional null mice. Drug Metab Dispos 39:2169-2173.
3. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, and Schmeiser HH et al. (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD (P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65:2644-2652. (Pubitemid 40490063)
4. Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singh R, Gamboa da Costa G, Schmitz OJ, and Farmer PB et al. (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: Experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29:656-665. (Pubitemid 351404884)
5. Collier R (2009) Drug development cost estimates hard to swallow. CMAJ 180: 279-280.
6. Cuatrecasas P (2006) Drug discovery in jeopardy. J Clin Invest 116:2837-2842. (Pubitemid 44684465)
7. Eichelbaum M, Ingelman-Sundberg M, and Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119-137. (Pubitemid 43261982)
8. Felmlee MA, Lon HK, Gonzalez FJ, and Yu AM (2008) Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36:435-441. (Pubitemid 351185758)
9. Ferguson CS and Tyndale RF (2011) Cytochrome P450 enzymes in the brain: Emerging evidence of biological significance. Trends Pharmacol Sci 32:708-714.
10. Finn RD, McLaren AW, Carrie D, Henderson CJ, and Wolf CR (2007) Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: A new model for studying the functions of the P450 system. J Pharmacol Exp Ther 322:40-47. (Pubitemid 46956358)
11. Finn RD, McLaughlin LA, Hughes C, Song C, Henderson CJ, and Roland Wolf C (2011) Cytochrome b5 null mouse: A new model for studying inherited skin disorders and the role of unsaturated fatty acids in normal homeostasis. Transgenic Res 20:491-502.
12. Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB, Henderson CJ, and Wolf CR (2008) Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J Biol Chem 283:31385-31393.
13. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, Yang W, Zhang L, and Ding X (2003) Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: Impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 278:25895-25901. (Pubitemid 36835351)
14. Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, and Scheer N (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518-528.
15. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, and Wolf CR (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278: 13480-13486. (Pubitemid 36800122)
16. Johansson I and Ingelman-Sundberg M (2011) Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 120:1-13.
17. Levová K, Moserová M, Kotrbová V, Sulc M, Henderson CJ, Wolf CR, Phillips DH, Frei E, Schmeiser HH, and Mares J et al. (2011) Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: Studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci 121:43-56.
18. McLaughlin LA, Ronseaux S, Finn RD, Henderson CJ, and Roland Wolf C (2010) Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolism. Mol Pharmacol 78:269-278.
19. Miller WL (2005) Minireview: Regulation of steroidogenesis by electron transfer. Endocrinology 146:2544-2550. (Pubitemid 40695556)
20. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162. (Pubitemid 35246494)
21. Nerurkar PV, Park SS, Thomas PE, Nims RW, and Lubet RA (1993) Methoxyresorufin and benzyloxyresorufin: Substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochem Pharmacol 46:933-943. (Pubitemid 23272776)
22. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
23. Paine MJI, Scrutton NS, Munro AW, Gutierrez A, Roberts GCK, and Wolf CR (2005) Electron transfer partners of cytochrome 450, in Cytochrome P450: Structure, Mechanism, and Biochemistry 3rd ed (Ortiz de Montellano PR ed) pp 115-148, Kluwer Academic, Plenum, New York.
24. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, and Wolf CR (2005) Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: Studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res 65:4211-4217. (Pubitemid 40775659)
25. Plant N (2004) Strategies for using in vitro screens in drug metabolism. Drug Discov Today 9:328-336. (Pubitemid 38373652)
26. Potega A, Dabrowska E, Niemira M, Kot-Wasik A, Ronseaux S, Henderson CJ, Wolf CR, and Mazerska Z (2011) The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s. Drug Metab Dispos 39:1423-1432.
27. Prosser DE and Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29:664-673. (Pubitemid 39491265)
28. Roma GW, Crowley LJ, and Barber MJ (2006) Expression and characterization of a functional canine variant of cytochrome b5 reductase. Arch Biochem Biophys 452:69-82. (Pubitemid 44107330)
29. Romano MC, Eckardt RD, Bender PE, Leonard TB, Straub KM, and Newton JF (1987) Biochemical characterization of hepatic microsomal leukotriene B4 hydroxylases. J Biol Chem 262:1590-1595.
30. Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, and Wolf CR (2012) Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63-72.
31. Schenkman JB and Jansson I (2003) The many roles of cytochrome b5. Pharmacol Ther 97:139-152.
32. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Frei E, Schmeiser HH, and Phillips DH (2005) Molecular mechanism of genotoxicity of the environmental pollutant 3-nitrobenzanthrone. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149: 191-197.
33. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH, and Frei E (2008) Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226:318-327. (Pubitemid 351172414)
34. Strobel HW and Dignam JD (1978) Purification and properties of NADPHcytochrome P-450 reductase. Methods Enzymol 52:89-96.
35. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, and Rosing H et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
36. van Waterschoot RA and Schinkel AH (2011) A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: Recent insights from knockout and transgenic mice. Pharmacol Rev 63:390-410.
37. Yu AM, Idle JR, and Gonzalez FJ (2004) Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metab Rev 36:243-277. (Pubitemid 38802489)
38. Zhang H, Hamdane D, Im SC, and Waskell L (2008) Cytochrome b5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J Biol Chem 283:5217-5225.
39. Zhang H, Myshkin E, and Waskell L (2005) Role of cytochrome b5 in catalysis by cytochrome P450 2B4. Biochem Biophys Res Commun 338:499-506. (Pubitemid 41540596)
40. Zhang QY, Fang C, Zhang J, Dunbar D, Kaminsky L, and Ding X (2009) An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: Direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine. Drug Metab Dispos 37:651-657.